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Résumé en
anglais
Morbidity and mortality from ischemic heart disease (IHD) and heart failure (HF)
remain significant in Europe and are increasing worldwide. Patients with IHD or HF
might benefit from novel therapeutic strategies, such as cell-based therapies. We
recently discussed the therapeutic potential of cell-based therapies and provided
recommendations on how to improve the therapeutic translation of these novel
strategies for effective cardiac regeneration and repair. Despite major advances in
optimizing these strategies with respect to cell source and delivery method, the
clinical outcome of cell-based therapy remains unsatisfactory. Major obstacles are the
low engraftment and survival rate of transplanted cells in the harmful
microenvironment of the host tissue, and the paucity or even lack of endogenous cells
with repair capacity. Therefore, new ways of delivering cells and their derivatives are
required in order to empower cell-based cardiac repair and regeneration in patients
with IHD or HF. Strategies using tissue engineering (TE) combine cells with matrix
materials to enhance cell retention or cell delivery in the transplanted area, and have
recently received much attention for this purpose. Here, we summarize knowledge on
novel approaches emerging from the TE scenario. In particular, we will discuss how
combinations of cell/bio-materials (e.g., hydrogels, cell sheets, prefabricated matrices,
microspheres, and injectable matrices) combinations might enhance cell retention or
cell delivery in the transplantation areas and thereby increase the success rate of cell
therapies for IHD and HF. We will not focus on the use of classical engineering
approaches, employing fully synthetic materials, because of their unsatisfactory
material properties which render them not clinically applicable. The overall aim of this
Position Paper from the ESC Working Group Cellular Biology of the Heart is to provide
recommendations on how to proceed in research with these novel tissue engineering
strategies combined with cell-based therapies to boost cardiac repair in the clinical
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